Imagine a diagnosis of early-stage stomach or esophageal cancer – a terrifying prospect made even worse by the high risk of recurrence, even after surgery and chemotherapy. But what if there was a way to significantly reduce that risk, offering a real chance at a cure? Well, there's some amazing news on that front.
AstraZeneca's Imfinzi (durvalumab), in combination with standard chemotherapy, has just been approved in the US as the first and only perioperative immunotherapy for patients with early-stage gastric and gastroesophageal junction (GEJ) cancers. This approval marks a significant shift in how we approach these challenging cancers, offering hope where it was once scarce.
This groundbreaking approval is specifically for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The treatment regimen involves a combination of Imfinzi and FLOT chemotherapy (a cocktail of fluorouracil, leucovorin, oxaliplatin, and docetaxel) before surgery (neoadjuvant), followed by Imfinzi and chemotherapy after surgery (adjuvant), and then Imfinzi alone (monotherapy) to really hammer the cancer into remission.
But here's where it gets controversial... Some doctors argue that such aggressive treatment protocols, while potentially life-saving, can also be incredibly taxing on the patient's body, leading to significant side effects and impacting their quality of life. Others argue the survival benefits outweigh the risks, especially in cancers with high recurrence rates. What do you think? Is the potential for longer life worth the increased burden of treatment? Let us know in the comments below!
This approval, granted Priority Review by the FDA, is based on the compelling results of the MATTERHORN Phase III trial. This trial demonstrated a remarkable 29% reduction in the risk of disease progression, recurrence, or death with the Imfinzi regimen compared to chemotherapy alone. What’s more, it also showed a 22% reduction in the risk of death.
To break that down a little further: the MATTERHORN trial meticulously tracked how long patients lived without the cancer returning or worsening (event-free survival, or EFS) and how long they lived overall (overall survival, or OS). The EFS results were initially presented at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine. The OS results were then revealed at the European Society for Medical Oncology (ESMO) Congress. These presentations highlight the rigor and significance of the findings.
Gastric cancer remains a major global health challenge, ranking as the fifth leading cause of cancer death worldwide. Every year, nearly one million people receive this diagnosis. In the US alone, approximately 6,500 patients with early-stage and locally advanced gastric or GEJ cancer receive drug treatment annually. That’s a lot of lives potentially impacted by this new treatment option.
According to Dave Fredrickson, Executive Vice President of AstraZeneca's Oncology Haematology Business Unit, this approval represents a “new clinical paradigm” for patients. He emphasizes the “durable survival benefit” offered by Imfinzi plus FLOT, further validating the perioperative approach – treating cancer both before and after surgery – and underscoring AstraZeneca's commitment to bringing innovative treatments to early-stage cancers where the ultimate goal is a cure.
Yelena Y. Janjigian, MD, a leading expert in gastrointestinal oncology at Memorial Sloan Kettering Cancer Center (MSK) and the principal investigator of the MATTERHORN trial, describes this approval as “opening an entirely new chapter” in the treatment of early-stage disease. She highlights that almost 70% of patients were still alive three years after treatment with the Imfinzi-based regimen. Crucially, this survival benefit was observed regardless of the patient's PD-L1 status (a biomarker often used to predict response to immunotherapy), making it a potential option for a wider range of patients.
Aki Smith, Founder and Executive Director of Hope for Stomach Cancer, offers a deeply personal perspective, drawing on her experience as a caregiver to her father. She emphasizes the long-standing need for improved outcomes in these cancers, where recurrence rates have been stubbornly high. This approval, she says, “represents a major step forward in improving outcomes and offering renewed hope.”
Delving deeper into the MATTERHORN trial results, the interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death compared to chemotherapy alone. The median EFS (the time until the cancer progressed or returned) wasn't even reached in the Imfinzi arm, while it was 32.8 months in the chemotherapy-only arm. At one year, approximately 78.2% of patients in the Imfinzi arm were event-free, compared to 74.0% in the chemotherapy arm. By two years, the EFS rates were 67.4% and 58.5%, respectively, showing the sustained benefit of Imfinzi.
The final overall survival (OS) analysis revealed a 22% reduction in the risk of death with the Imfinzi regimen. An estimated 69% of patients treated with Imfinzi were still alive at three years, compared to 62% in the chemotherapy-only group. Importantly, the survival curves continued to separate over time, indicating that the benefit of Imfinzi may become even more pronounced with longer follow-up. This benefit was seen across patients, irrespective of their PD-L1 status.
Safety is, of course, paramount. The safety profile of Imfinzi in combination with FLOT chemotherapy was consistent with what was already known about each medicine. The percentage of patients who successfully completed surgery was similar in both treatment groups. The rates of Grade 3 or higher adverse events (serious side effects) were also comparable between the two arms (71.6% in the Imfinzi + FLOT arm and 71.2% in the FLOT-only arm).
The US regulatory submission for Imfinzi was reviewed under Project Orbis, a collaborative initiative that allows for concurrent submission and review of oncology medicines among international partners. As part of this project, the Imfinzi and FLOT perioperative regimen is also being evaluated by regulatory authorities in Australia, Canada, and Switzerland. Furthermore, regulatory applications are currently under review in the European Union (EU), Japan, and several other countries, potentially expanding access to this treatment for patients worldwide.
This approval of Imfinzi marks a significant step forward in the fight against gastric and gastroesophageal junction cancers. However, it's important to remember that this is just one piece of the puzzle. Continued research and development are crucial to further improve outcomes and quality of life for patients facing these challenging diseases. What are your thoughts on the future of cancer treatment? What other innovations do you hope to see in the years to come? Share your opinions below!
